Search results
Results from the WOW.Com Content Network
Pergolide, sold under the brand name Permax and Prascend (veterinary) among others, is an ergoline-based dopamine receptor agonist used in some countries for the treatment of Parkinson's disease. Parkinson's disease is associated with reduced dopamine synthesis in the substantia nigra of the brain .
On December 30, 2016 Boehringer Ingelheim completed a swap of their OTC business for Sanofi's animal health business. Merial is now owned by Boehringer Ingelheim and combined with their animal health business, Boehringer Ingelheim Vetmedica, to form Boehringer Ingelheim Animal Health.
C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies , and the largest private one.
In 2013 Boehringer received clearance for ViSiGi 3D gastric sizing tube for single patient use. This is the first FDA-approved calibration system intended for sleeve gastrectomy. The world's first and only 4-mode suction regulator was introduced in 2015. Boehringer spirometers were selected by the American Medical Research Expedition to Everest.
The Medicaid Drug Rebate Program is a program in the United States that was created by the Omnibus Budget Reconciliation Act of 1990 (OBRA'90). The program establishes mandatory rebates that drug manufacturers must pay state Medicaid agencies related to the dispensing of outpatient prescription drugs covered by Medicaid .
The company was founded in 1999 as the website How2.com. In 2001, the company shifted its business to rebate and reward programs. Parago was founded by venture capital firm T. H. Lee of New York and was formerly known by the name Parago Rebates HQ. The firm has experienced significant growth and expansion in the early 2000s.
As of May 2013, Boehringer and Lilly had submitted applications for marketing approval to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). [50] Empagliflozin was approved in the European Union in May 2014, [13] and was approved in the United States in August 2014.
And Boehringer Ingelheim is making it available to all Americans, regardless of insurance status," Gemmell said. Cyltezo will sell for $550, a 92% discount from the Humira list price of about $7,000.